Search
forLearn
5 / 801 resultslearn oligopeptide-71
learn vitamin k
learn potassium
learn copper tripeptide-1
Research
5 / 1000+ results
research Ginseng phytochemicals as therapeutics in oncology: Recent perspectives
Ginseng may help treat cancer and reduce treatment side effects, but more research is needed.
research Effect of topical application of raspberry ketone on dermal production of insulin-like growth factor-I in mice and on hair growth and skin elasticity in humans
Raspberry ketone may help grow hair and improve skin elasticity.
research Biosynthesis and function of rhizobacterial secondary metabolites in plant abiotic stress tolerance
Rhizobacterial strain RT3 helps lettuce survive drought by producing protective substances like proline.
research Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice.
Lack of KSR1 stops certain skin tumors in mice.
research A new mutation Rim3 resembling Re den is mapped close to retinoic acid receptor alpha (Rara) gene on mouse Chromosome 11
Community Join
5 / 1000+ results
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
community PG causing irritation when applying RU
The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.
community Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
community KX826 is better than RU58841. A legitimate option for those who cant use fin or dut.
KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.